John M. Maraganore's most recent trade in Hemab Therapeutics Holdings Inc. was a trade of 107,338 Warrants (Right to Buy) done . Disclosure was reported to the exchange on Jan. 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Hemab Therapeutics Holdings | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 107,338 | 107,338 | - | - | Warrants (Right to Buy) | |
| Hemab Therapeutics Holdings | John M. Maraganore | Director | 29 Jan 2026 | 17,974 | 17,974 | - | - | Common Stock | ||
| Hemab Therapeutics Holdings | John M. Maraganore | Director | 29 Jan 2026 | 17,974 | 35,948 | - | - | Common Stock | ||
| Hemab Therapeutics Holdings | John M. Maraganore | Director | 29 Jan 2026 | 817 | 0 | - | - | Series C Preferred Stock | ||
| Hemab Therapeutics Holdings | John M. Maraganore | Director | 29 Jan 2026 | 817 | 0 | - | - | Series B Preferred Stock | ||
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Rapport Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 33,662 | 33,662 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 23,114 | 23,114 | - | - | Stock Option (Right to Buy) | |
| ProKidney Corp Ordinary | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 48,128 | 48,128 | - | - | Director stock option (right to buy) | |
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 16,532 | 16,532 | - | - | Stock Option (Right to Buy) | |
| Agios Pharma Inc | John M. Maraganore | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 1,500 | 28,528 (0%) | 0% | 0 | Common stock | |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 10,391 | 10,391 | - | - | Stock Option (Right to Buy) | |
| ProKidney Corp Ordinary | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 614,013 | 614,013 | - | - | Common Units in ProKidney LP | |
| ProKidney Corp Ordinary | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2022 | 614,013 | 614,013 | - | - | Class B Ordinary Shares | |
| Agios Pharma Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Agios Pharma Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Agios Pharma Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 30,028 (0%) | 0% | 0 | Common stock | |
| Agios Pharma Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Kymera Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 14,167 | 234,299 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 189.13 per share. | 21 Dec 2021 | 6,315 | 227,984 (0%) | 0% | 189.1 | 1,194,356 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 186.02 per share. | 21 Dec 2021 | 319 | 227,663 (0%) | 0% | 186.0 | 59,340 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 190.50 per share. | 21 Dec 2021 | 2 | 227,982 (0%) | 0% | 190.5 | 381 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 2,368 | 22,632 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 10 Dec 2021 | 2,368 | 220,132 (0%) | 0% | 42.2 | 99,977 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 1,124 | 63,876 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 10 Dec 2021 | 1,124 | 216,925 (0%) | 0% | 89.0 | 99,980 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 96.45 per share. | 10 Dec 2021 | 1,036 | 215,801 (0%) | 0% | 96.4 | 99,922 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 1,036 | 73,964 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 839 | 51,661 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 119.13 per share. | 10 Dec 2021 | 839 | 217,764 (0%) | 0% | 119.1 | 99,950 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2021 | 33,978 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.10 per share. | 12 Nov 2021 | 33,978 | 248,743 (0%) | 0% | 7.1 | 241,244 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 172.22 per share. | 12 Nov 2021 | 14,518 | 216,118 (0%) | 0% | 172.2 | 2,500,290 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 170.36 per share. | 12 Nov 2021 | 10,365 | 238,378 (0%) | 0% | 170.4 | 1,765,781 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 171.35 per share. | 12 Nov 2021 | 7,742 | 230,636 (0%) | 0% | 171.4 | 1,326,592 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 173.25 per share. | 12 Nov 2021 | 683 | 215,435 (0%) | 0% | 173.3 | 118,330 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 174.34 per share. | 12 Nov 2021 | 670 | 214,765 (0%) | 0% | 174.3 | 116,808 | Common Stock |
| Beam Therapeutics Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Nov 2021 | 13,133 | 13,133 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2021 | 33,979 | 33,978 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.10 per share. | 13 Aug 2021 | 33,979 | 248,744 (0%) | 0% | 7.1 | 241,251 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 199.92 per share. | 13 Aug 2021 | 23,336 | 218,807 (0%) | 0% | 199.9 | 4,665,333 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 198.93 per share. | 13 Aug 2021 | 4,160 | 242,143 (0%) | 0% | 198.9 | 827,549 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 200.84 per share. | 13 Aug 2021 | 3,828 | 214,979 (0%) | 0% | 200.8 | 768,816 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 198.02 per share. | 13 Aug 2021 | 2,441 | 246,303 (0%) | 0% | 198.0 | 483,367 | Common Stock |
| Alnylam Pharma Inc | John M. Maraganore | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 201.55 per share. | 13 Aug 2021 | 214 | 214,765 (0%) | 0% | 201.6 | 43,132 | Common Stock |
| Agios Pharma Inc | John M. Maraganore | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 28 May 2021 | 3,415 | 26,757 (0%) | 0% | 0 | Common stock | |
| Agios Pharma Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 28,443 (0%) | 0% | 0 | Common stock | |
| Agios Pharma Inc | John M. Maraganore | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | |
| Agios Pharma Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | |
| Agios Pharma Inc | John M. Maraganore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit |